IBO (Impact BioMedical) Tariff Resilience Score: 5/10 (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IBO Impact BioMedical Inc IBO
10 GF Score
Price $0.47
! 6 Warning Signs
View Full Analysis

What is Impact BioMedical Tariff Resilience Score?

Impact BioMedical IBO +6.82% 10 Tariff Resilience Score is 5 as of Aug. 14, 2026. GuruFocus rates IBO with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 1,362 Biotechnology companies, Impact BioMedical ranks better than 62.48% on this metric.

Impact BioMedical has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Impact BioMedical has Impact BioMedical's reliance on international partnerships for R&D and potential raw material imports exposes it to tariff risks. However, its focus on innovation and potential for alternative sourcing provides some mitigation.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Impact BioMedical might have Average Resilient.

Impact BioMedical  (AMEX:IBO) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Impact BioMedical Tariff Resilience Score Related Terms

IBO vs ATYR, MCRB, TIL: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Impact BioMedical's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Impact BioMedical Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Impact BioMedical's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Impact BioMedical's Tariff Resilience Score falls into.


IBO
10GF Score
Impact BioMedical Inc IBO
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Impact BioMedical (IBO) has a Tariff Resilience Score of 5 as of Aug. 14, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Impact BioMedical ranks #511 out of 1362 companies in the Biotechnology industry, placing it in the top 37.5%.
Is Impact BioMedical's Tariff Resilience Score too high?
Impact BioMedical's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Impact BioMedical's value of 5 is 25% above this industry median. Based on the distribution chart, Impact BioMedical ranks #511 out of 1362 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Impact BioMedical has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Impact BioMedical's Tariff Resilience Score compare to ATYR and MCRB?
According to the Biotechnology industry distribution chart, Impact BioMedical ranks #511 out of 1362 companies for Tariff Resilience Score. This puts Impact BioMedical in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Impact BioMedical's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,362 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Impact BioMedical's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impact BioMedical's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impact BioMedical stock overvalued right now?
Impact BioMedical (IBO) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Impact BioMedical's overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Impact BioMedical (IBO), the current Tariff Resilience Score is 5 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Impact BioMedical Business Description

Address 1400 Broadfield Boulevard, Suite 130, Houston, TX, USA, 77084
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
10GF Score

Get the complete analysis for IBO

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price